Sagent Holding Co.
Formerly NHS PHARMACEUTICALS
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2010 | $6 M | No. 3 | $2 to $10 million | equity | SEC | |
| Mar 2010 | $10 M | No. 2 | $2 to $10 million | equity | SEC | |
| May 2009 | $30 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Sagent Holding Co. chose not to state its revenue in its newest notice of a funding round (Sep 2010).
SEC Form D · Sep 2010
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Sep 2010
That is all the official record says: Sagent Holding Co. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| China Harvest Fund II, LP | Fund or asset manager | not stated | not stated | Held Series B-1 preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| China Renaissance Capital Investment II GP | Fund or asset manager | not stated | not stated | Held Series B-1 preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| China Renaissance Capital Investment II, L.P. | Fund or asset manager | not stated | not stated | Held Series B-1 preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Key Gate Investments Ltd | Fund or asset manager | not stated | not stated | Held Series B-1 preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 10 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jeffrey Yordon | Executive officer | Sep 2010 |
| Ronald Pauli | Executive officer | Sep 2010 |
| Ronald E. Pauli | Executive officer | Jun 2009 |
| Anthony Krizman | Director | Sep 2010 |
| Chen Yu | Director | Sep 2010 |
| Frank Kung | Director | Sep 2010 |
| James Sperans | Director | Sep 2010 |
| Jeffrey Yordon | Director | Sep 2010 |
| Mark Qiu | Director | Sep 2010 |
| Robert Flanagan | Director | Sep 2010 |